Haemonetics Corporation HAE
NYSE
| 06/27/2026 | 03/28/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -2.01% | 2.18% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.01% | 2.18% | |||
| Cost of Revenue | -8.31% | 8.39% | |||
| Gross Profit | 2.69% | -2.02% | |||
| SG&A Expenses | -7.16% | 18.31% | |||
| Depreciation & Amortization | -2.74% | -4.04% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.62% | 11.40% | |||
| Operating Income | 26.61% | -32.51% | |||
| Income Before Tax | 267.52% | -147.35% | |||
| Income Tax Expenses | 276.49% | -154.16% | |||
| Earnings from Continuing Operations | 263.85% | -145.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 263.85% | -145.03% | |||
| EBIT | 26.61% | -32.51% | |||
| EBITDA | 26.96% | -29.73% | |||
| EPS Basic | 266.94% | -145.59% | |||
| Normalized Basic EPS | 37.44% | -40.03% | |||
| EPS Diluted | 264.87% | -145.97% | |||
| Normalized Diluted EPS | 36.40% | -39.78% | |||
| Average Basic Shares Outstanding | -1.87% | -1.21% | |||
| Average Diluted Shares Outstanding | -1.12% | -1.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||